ProMIS Neurosciences Inc.

ProMIS Neurosciences is a TSX listed biotech company (trading symbol: PMN.TO), headquartered in Toronto, Ontario and with offices in Cambridge, Massachusetts. The mission of ProMIS is to discover and develop precision medicine therapeutics for effective treatment of neurodegenerative diseases, in particular Alzheimer’s disease and ALS.

ProMIS Neurosciences’ proprietary target discovery engine is based on the use of two, complementary techniques. The Company applies its thermodynamic, computational discovery platform—ProMIS™ and Collective Coordinates — to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. Using this unique "precision medicine" approach, ProMIS Neurosciences is developing novel antibody therapeutics and specific companion diagnostics for Alzheimer’s disease and ALS. The company has also developed two proprietary technologies to specifically identify very low levels of misfolded proteins in a biological sample. In addition, ProMIS Neurosciences owns a portfolio of therapeutic and diagnostic patents relating to misfolded SOD1 in ALS, and currently has a preclinical monoclonal antibody therapeutic against this target.

For further information please consult the Company's website at:
www.promisneurosciences.com

Follow us on Twitter

Like us on LinkedIn

Contact Information:

For media inquiries, please contact:

 

Scott Santiamo

RussoPartners/LLC

Scott.Santiamo@russopartnersllc.com

Office: (212) 845-4235

Mobile: (718) 344-5843

cbealamaro@streetwisereports.com

 

or contact

 

Dr. Elliot Goldstein

President and Chief Executive Officer, ProMIS Neurosciences Inc.

Tel. 415 341-5783

Elliot.goldstein@promisneurosciences.com

Latest

Oct 08, 2019, 07:30 ET ProMIS Neurosciences Identifies Novel Antibody Candidates for Multiple System Atrophy

Antibodies show highly selective binding to pathogenic forms of alpha-synuclein implicated in multiple system atrophy TORONTO and CAMBRIDGE, MA, Oct. 8, 2019 /CNW/ - ProMIS Neurosciences, Inc. (TSX:...


Sep 16, 2019, 07:30 ET ProMIS Neurosciences Executive Chairman Eugene Williams to Speak on Panel at Fall Investor Summit

TORONTO and CAMBRIDGE, MA, Sept. 16, 2019 /CNW/ - ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics...


Sep 03, 2019, 07:30 ET ProMIS Neurosciences to Present at HC Wainwright Investment Conference

Company to showcase its innovative Alzheimer's, Parkinson's and ALS programs TORONTO and CAMBRIDGE, MA, Sept. 3, 2019 /CNW/ - ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology...


Aug 27, 2019, 07:30 ET ProMIS Neurosciences Appoints Internationally Recognized Researcher in Alzheimer's Disease in Down Syndrome Dr. Andre Strydom to its Scientific Advisory Board

TORONTO and CAMBRIDGE, MA, Aug. 27, 2019 /CNW/ - ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics...


Aug 13, 2019, 07:30 ET ProMIS Neurosciences Announces Second Quarter 2019 Results

Company continues to expand its portfolio of highly selective antibodies targeting root cause of Alzheimer's, ALS and Parkinson's disease TORONTO and CAMBRIDGE, MA, Aug. 13, 2019 /CNW/ - ProMIS...


Jul 24, 2019, 07:30 ET ProMIS Neurosciences Announces Results of Annual Meeting of Shareholders

ProMIS' shareholders show overwhelming support for all resolutions TORONTO and CAMBRIDGE, MA, July 24, 2019 /CNW/ - ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company...


Jul 18, 2019, 15:00 ET ProMIS Neurosciences Highlights Data for PMN310 at AAIC 2019

Alzheimer's Association International Conference includes oral session on PMN310 for Alzheimer's disease and poster presentation on ALS TORONTO and CAMBRIDGE, MA, July 18, 2019 /CNW/ - ProMIS...


Jul 10, 2019, 07:30 ET ProMIS Neurosciences to Present Data at 2019 Alzheimer's Association International Conference

Abstracts selected for oral and poster presentation TORONTO and CAMBRIDGE, MA, July 10, 2019 /CNW/ - ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the...


Jul 09, 2019, 07:30 ET ProMIS Neurosciences' Data for Alzheimer's Disease Clinical Candidate PMN310 Published in Scientific Reports

Nature Research Journal highlights data supporting the therapeutic potential of PMN310 against the toxic oligomer form of amyloid beta, a root cause of Alzheimer's disease TORONTO and CAMBRIDGE, MA,...


Jun 27, 2019, 07:30 ET ProMIS Neurosciences' PMN310 Shows Greater Therapeutic Potential vs. Other Amyloid-Beta-Directed Antibodies

Data presented at Keystone Symposium on Neurodegenerative Diseases TORONTO and CAMBRIDGE, MA, June 27, 2019 /CNW/ - ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company...


Jun 26, 2019, 07:30 ET ProMIS Neurosciences Closing Private Placement

/NOT FOR DISTRIBUTION TO US NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/ TORONTO, June 26, 2019 /CNW/ - ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company...


Jun 19, 2019, 07:30 ET ProMIS Neurosciences Appoints Renowned Parkinson's Disease Expert Dr. C. Warren Olanow to Scientific Advisory Board

Internationally recognized leader in neurodegenerative diseases to advise on programs selectively targeting the toxic oligomer TORONTO and CAMBRIDGE, MA, June 19, 2019 /CNW/ - ProMIS Neurosciences,...


Jun 05, 2019, 07:30 ET ProMIS Neurosciences Presents Lead Program for Alzheimer's Disease at Prestigious Keystone Symposia Scientific Conference

Neurodegenerative Diseases: New Insights and Therapeutic Opportunities to advance discussion about therapies for Alzheimer's disease among world's leading researchers TORONTO and CAMBRIDGE, MA, June...


May 29, 2019, 07:30 ET ProMIS Neurosciences' Eugene Williams to Present at JLABS' Conference on Innovations in Neurodegenerative Diseases

TORONTO and CAMBRIDGE, MA, May 29, 2019 /CNW/ - ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics...


May 28, 2019, 07:30 ET ProMIS Neurosciences Identifies Novel Antibodies for Alzheimer's Disease with Selectivity for the Neurotoxic Form of Tau

Pipeline offers critical "one-two punch" in potential treatment arsenal for Alzheimer's disease TORONTO and CAMBRIDGE, MA, May 28, 2019 /CNW/ - ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a ...


May 14, 2019, 07:30 ET ProMIS Neurosciences Announces First Quarter 2019 Results

Company continues to show significant progress on developing highly selective antibodies targeting root cause of Alzheimer's and Parkinson's diseases and ALS TORONTO and CAMBRIDGE, MA, May 14, 2019...


Apr 23, 2019, 07:30 ET ProMIS Neurosciences to Participate in the Think Equity Investor Conference

Company to showcase its innovative Alzheimer's, Parkinson's and ALS programs TORONTO and CAMBRIDGE, MA, April 23, 2019 /CNW/ - ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology...


Mar 26, 2019, 07:30 ET ProMIS Neurosciences to Participate in Microcap Spring Investor Summit 2019

Company to showcase innovative programs addressing urgent need for disease-modifying therapies selectively targeting toxic oligomers in Alzheimer's and Parkinson's diseases and ALS TORONTO and...


Mar 21, 2019, 14:47 ET Aducanumab Failure: Selectivity for the Toxic Oligomer is Essential to Treating Root Cause of Alzheimer's Disease

Discontinued aducanumab phase 3 studies emphasize urgent need for therapies that target the toxic oligomer with exacting precision TORONTO and CAMBRIDGE, MA, March 21, 2019 /CNW/ - ProMIS...


Mar 19, 2019, 07:30 ET ProMIS Neurosciences to Present Data for Potential Best-in-Class Antibody Candidates for Parkinson's Disease at AD/PD™ 2019 Conference

Selected for podium presentation: novel antibody candidates bind only the toxic species of alpha-synuclein offering potential advantages over less selective therapies in development TORONTO and...


Mar 15, 2019, 07:30 ET ProMIS Neurosciences Announces Fiscal Year 2018 Annual Results

TORONTO, ON and CAMBRIDGE, MA, March 15, 2019 /CNW/ - ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics...


Feb 21, 2019, 07:30 ET ProMIS Neurosciences Adds Pharmaceutical Leader Timothy Rothwell to Board of Advisors

Former Sanofi U.S. Chairman to provide guidance and assistance to ProMIS business development strategies and partnering plans TORONTO and CAMBRIDGE, MA, Feb. 21, 2019 /CNW/ - ProMIS Neurosciences,...


Feb 12, 2019, 07:30 ET Parkinson's Disease: ProMIS Neurosciences Identifies Several Antibody Drug Candidates Showing Best-in-Class Selectivity for Toxic Forms of Alpha-Synuclein Compared to other Therapeutic Antibodies in

Competitive Differentiation of ProMIS Antibodies is Key to Ongoing Partnering Discussions with Large Pharmaceutical Companies TORONTO and CAMBRIDGE, MA, Feb. 12, 2019 /CNW/ - ProMIS Neurosciences,...


Jan 31, 2019, 07:30 ET Selectivity for the Toxic Oligomer Essential to Treating Root Cause of Alzheimer's Disease

Discontinued crenezumab phase 3 studies underscore urgent need for therapies that target the toxic oligomer with extraordinary precision TORONTO and CAMBRIDGE, MA, Jan. 31, 2019 /CNW/ - ProMIS...


Jan 23, 2019, 07:30 ET ProMIS Neurosciences Completes Private Placement of Units

/NOT FOR DISTRIBUTION TO US NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES./ TORONTO, Jan. 23, 2019 /CNW/ - ProMIS Neurosciences Inc. ("ProMIS" or the "Company") (TSX: PMN);...